Signal Projections put 25 million Americans on GLP-1 treatment by 2030

Summary

McKinsey cites recent projections that as many as 25 million people in the United States could be on GLP-1 treatments by 2030. The figure comes from a February 2026 JPMorgan Chase analysis of demand for and supply of weight-loss drugs. It builds on evidence that adoption is already widespread, with roughly one in six US households having at least one member who had tried GLP-1s by July 2024. Earlier research found such households reduced grocery spending by about 6 percent within six months, although many users stopped and returned to prior spending. The report places this outlook within the health revolution, pointing out that GLP-1 use is also creating new needs, such as products that help preserve muscle and bone.